CoChat

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

Open access
Perna, Simone, Mainardi, Manuela, Astrone, Paolo, Gozzer, Carlotta, Biava, Anna, Bacchio, Ruben, Spadaccini, Daniele, Solerte, Sebastiano Bruno, Rondanelli, Mariangela · 2018 · Clinical Pharmacology: Advances and Applications
Cited by 54

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Aim: The aim of the present study is to examine the effects on cognitive performance, anthropometric measures, and metabolic markers in 2 different treatments: Incretins vs sodium-glucose co-transporter-2 inhibitors (SGLT2-I). Materials and methods: A randomized controlled clinical trial was carried out on 39 elderly subjects (23 men and 16 women) with type 2 diabetes mellitus, with a mean age of 77.21±8.07 years. Body mass index (BMI) of 29.92±4.31 kg/m 2 and a cognitive status measured by a Mini Mental State Examination (scores >27 points). The subjects were on a 3-month treatment with a maximal dose of metformin as a stable regime, with the addition of incretins (liraglutide at doses of up to 1.8 mg/d; vildagliptin at 100 mg/d; sitagliptin 100 mg/d; and linagliptin 5 mg/d), or SGLT2-I (canagliflozin 300 mg/d; empagliflozin 25 mg/d; and dapagliflozin 10 mg/d). Glucose control was monitored by fasting glucose and glycosylated hemoglobin. Cognitive performance (by way of Verbal Fluency Test, Attentive Matrices Test, and Babcock Story Recall Test), anthropometric measures, and plasma lipids were also evaluated. Results: Cognitive status did not change significantly during the 12 months of treatment in either group: Verbal Fluency Test: (SGLT2-I: P =1.00, incretins: P =0.598); Babcock Story Recall Test (SGLT2-I: P =0.391; incretins: P =0.351); and Attentive Matrices Test (SGLT2-I: P =0.679, incretins: P =0.901). SGLT2-I also resulted in a reduction in weight (–1.95 kg; P <0.05), in BMI (–0.69 kg/m 2 ; P <0.05) and an increase in high-density lipoprotein cholesterol (+5.73 mg/dl; P <0.01). Conclusion: Preliminary data show that patients treated with incretins and SGLT2-I have not suffered a reduction in cognitive performance during the 1 year of treatment. Metabolic outcome seemed to benefit, in particular, in patients who were treated with SGLT2-I. Keywords: SGLT-2 inhibitors, incretins, cognitive performance, cognitive impairment, metabolic outcome

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/cpaa.s164785

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 54

Metadata

Authors
Perna, S., Mainardi, M., Astrone, P., Gozzer, C., Biava, A., Bacchio, R., Spadaccini, D., Solerte, S. B., & Rondanelli, M.
Venue
Clinical Pharmacology: Advances and Applications
Published
2018-10
Volume
Volume 10
Pages
141-151
ISSN
1179-1438 (ISSN-L)
OpenAlex
W2896293484
Cited by
54
References
16
FWCI
3.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. https://app.cochat.ai/papers/10.2147/cpaa.s164785
The paper
Perna, S., Mainardi, M., Astrone, P., Gozzer, C., Biava, A., Bacchio, R., Spadaccini, D., Solerte, S. B., & Rondanelli, M. (2018). 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. Clinical Pharmacology: Advances and Applications. https://doi.org/10.2147/cpaa.s164785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.